A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
A phase 2 trial of Carboplatin, Mirvetuximab soravtansine, Bevacizumab in ovarian cancer, run by AbbVie, now recruiting.
Overview
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. is a phase 2 interventional study registered as NCT06890338 by AbbVie, with 140 participants planned, started 2025-11-21 and due to reach its primary completion in 2030-02. Interventions recorded: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin.
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Ovarian cancer.
- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Mirvetuximab soravtansine, Carboplatin, Ovarian cancer.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Mirvetuximab soravtansine, Ovarian cancer.